insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

SLRX · Salarius Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$749.8K-$61.8K$116.4K$75.5K-$137.2K$214.4K$243.0K-
SG&A$1.53M-$833.3K$849.2K$1.64M-$869.2K$1.25M$1.53M-
Total Operating Expenses$2.28M-$895.1K$965.6K$1.72M-$1.01M$1.47M$1.77M-
D&A$5.9K---$1.1K---$1.1K-
Operating Income($2.28M)-($895.1K)($965.6K)($1.72M)-($1.01M)($1.47M)($1.77M)-
Interest Expense----------
Income Tax----------
Net Income($2.22M)-($873.5K)($957.8K)($1.71M)-($972.1K)($1.42M)($1.72M)-
EPS - Basic($4.18)-($1.81)($0.45)($1.03)-($0.76)($2.37)($0.41)-
EPS - Diluted($4.18)-($1.81)($0.45)($1.03)-($0.76)($2.37)($0.41)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$7.82M$10.71M$4.81M$794.9K$1.80M$2.43M$3.28M$3.27M$4.37M$5.90M
Accounts Receivable----------
Inventory----------
Accounts Payable$936.0K$940.6K$1.10M$1.48M$1.47M$937.0K$165.8K$643.1K$714.0K$602.9K
Current Assets$8.36M$10.99M$6.06M$1.36M$2.31M$2.99M$3.82M$3.51M$4.83M$6.52M
Total Assets$8.42M$11.06M$6.10M$1.39M$2.34M$3.02M$3.86M$3.55M$4.88M$6.59M
Current Liabilities$4.55M$5.17M---$1.51M----
Long-term Debt----------
Total Liabilities$4.55M$5.17M$1.85M$2.22M$2.28M$1.51M$934.6K$1.18M$1.23M$1.30M
Stockholders' Equity$3.88M$5.89M$4.25M($829.7K)$61.9K$1.51M$2.92M$2.38M$3.65M$5.29M
Retained Earnings($96.67M)($94.44M)($85.46M)($84.59M)($83.63M)($81.92M)($80.46M)($79.49M)($78.06M)($76.35M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($2.89M)---($1.18M)---($1.35M)-
Investing Cash Flow----------
Financing Cash Flow$0---$545.6K---($172.8K)-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-26.4%--14.3%-68.8%-73.1%--25.2%-40.1%-35.1%-
Return on equity-57.4%--20.6%115.4%-2763.3%--33.2%-60.0%-47.0%-
Return on invested capital----------
Liquidity
Current ratio1.842.13---1.98----
Quick ratio1.842.13---1.98----
Cash ratio1.722.07---1.61----
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier2.171.881.44-1.6837.812.001.321.501.341.25
Liabilities / Assets0.540.470.301.600.970.500.240.330.250.20
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-32.9%-11.1%34.2%3.0%-60.3%63.0%67.3%-
Net income growth (YoY)-30.1%-10.1%32.8%0.3%-60.2%63.3%67.9%-
EPS growth (YoY)-305.8%--138.2%81.0%-151.2%--16.9%-65.7%81.6%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)6167.4%289.6%45.3%--98.3%-71.4%-51.9%-71.8%-34.3%-49.1%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Salarius Pharmaceuticals against the 5 most active filers in the same SIC group.